LYMNUTRO Trademark

Trademark Overview

On Tuesday, April 13, 2021, a trademark application was filed for LYMNUTRO with the United States Patent and Trademark Office. The USPTO has given the LYMNUTRO trademark a serial number of 90642264. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Saturday, October 28, 2023. This trademark is owned by X4 Pharmaceuticals, Inc.. The LYMNUTRO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of WHIM syndrome; Pharmaceutical preparations for the treatment of immunodeficiencies; Pharmaceutical preparations for the treatment of neutropenia; Pharmaceutical preparations for the treatment of Waldenström's macroglobulinemia; Pharmaceutical preparations for the treatment of cancer
lymnutro

General Information

Serial Number90642264
Word MarkLYMNUTRO
Filing DateTuesday, April 13, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateSaturday, October 28, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 7, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of WHIM syndrome; Pharmaceutical preparations for the treatment of immunodeficiencies; Pharmaceutical preparations for the treatment of neutropenia; Pharmaceutical preparations for the treatment of Waldenström's macroglobulinemia; Pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 20, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameX4 Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02134
Party NameX4 Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02134

Trademark Events

Event DateEvent Description
Tuesday, October 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, October 28, 2023SOU EXTENSION 4 GRANTED
Saturday, October 28, 2023SOU EXTENSION 4 FILED
Saturday, October 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, April 30, 2023SOU EXTENSION 3 GRANTED
Sunday, April 30, 2023SOU EXTENSION 3 FILED
Sunday, April 30, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 31, 2022SOU EXTENSION 2 GRANTED
Monday, October 31, 2022SOU EXTENSION 2 FILED
Monday, October 31, 2022SOU TEAS EXTENSION RECEIVED
Monday, October 31, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 31, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, October 31, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, October 31, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 29, 2022SOU EXTENSION 1 GRANTED
Friday, April 29, 2022SOU EXTENSION 1 FILED
Friday, April 29, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, November 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 7, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 7, 2021PUBLISHED FOR OPPOSITION
Wednesday, August 18, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 3, 2021ASSIGNED TO EXAMINER
Tuesday, July 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 16, 2021NEW APPLICATION ENTERED

Related Keywords

lymnutro pharmaceutical treatment preparations macroglobulinemia cancer waldenstr syndrome whim immunodeficiencies neutropenia